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ABSTRACT: The hypothesis in the current study is that the
simultaneous direct in vivo testing of thousands to millions of
systematically arranged mixture-based libraries will facilitate the
identiﬁcation of enhanced individual compounds. Individual
compounds identiﬁed from such libraries may have increased
speciﬁcity and decreased side eﬀects early in the discovery phase.
Testing began by screening ten diverse scaﬀolds as single
mixtures (ranging from 17 340 to 4 879 681 compounds) for
analgesia directly in the mouse tail withdrawal model. The “all X”
mixture representing the library TPI-1954 was found to produce
signiﬁcant antinociception and lacked respiratory depression and
hyperlocomotor eﬀects using the Comprehensive Laboratory Animal Monitoring System (CLAMS). The TPI-1954 library is a
pyrrolidine bis-piperazine and totals 738 192 compounds. This library has 26 functionalities at the ﬁrst three positions of diversity
made up of 28 392 compounds each (26 × 26 × 42) and 42 functionalities at the fourth made up of 19 915 compounds each (26
× 26 × 26). The 120 resulting mixtures representing each of the variable four positions were screened directly in vivo in the
mouse 55 °C warm-water tail-withdrawal assay (ip administration). The 120 samples were then ranked in terms of their
antinociceptive activity. The synthesis of 54 individual compounds was then carried out. Nine of the individual compounds
produced dose-dependent antinociception equivalent to morphine. In practical terms what this means is that one would not
expect multiexponential increases in activity as we move from the all-X mixture, to the positional scanning libraries, to the
individual compounds. Actually because of the systematic formatting one would typically anticipate steady increases in activity as
the complexity of the mixtures is reduced. This is in fact what we see in the current study. One of the ﬁnal individual compounds
identiﬁed, TPI 2213-17, lacked signiﬁcant respiratory depression, locomotor impairment, or sedation. Our results represent an
example of this unique approach for screening large mixture-based libraries directly in vivo to rapidly identify individual
compounds.
KEYWORDS: opioid, in vivo high-throughput screening, mixture-based combinatorial libraries, analgesia
■ INTRODUCTION
Although opioids are the front line therapeutics used for the
treatment of signiﬁcant pain, their use is limited by adverse side
eﬀects that include respiratory depression, tolerance, psycho-
logical eﬀects and addiction. These have serious consequences
for both individuals and society.1 Notwithstanding years of
study, there continues to be a need for novel chemical entities
demonstrating potent analgesia in conjunction with lacking the
classic side eﬀects of the currently utilized opiate therapeutics.
A common reality is that the majority of preclinical drug
candidates do not exhibit desirable drug-like properties and
have signiﬁcant side eﬀect proﬁles at later stages of testing. This
results in a high rate of attrition in the traditional drug
discovery process 2008.2 To circumvent a number of the
limitations of existing in vitro screening methods, we have
developed a platform technology that permits the testing of
tens of thousands to tens of millions of compounds as mixtures
directly in animal models of disease. The use of systematically
arranged libraries in positional scanning format.3−5 enables the
identiﬁcation of active functionalities at each variable position
in a given molecule. This in turn, enables individual compounds
to be readily identiﬁed, synthesized, and tested for their
analgesic properties.
Mixture-based synthetic libraries are highly eﬀective tools for
generating novel lead compounds in a fraction of the time and
cost of equivalent individual compound arrays.6−9 These large
libraries are composed of linear peptides (tens of millions to
trillions), cyclic peptides (5−10 million), peptidomimetics
(millions), as well as 7−8 million heterocyclic compounds,10−12
and trillions of nona-and deca-peptides.13 Such mixtures are
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eﬀective because the most active compounds in a given mixture
drive the activity found when such mixtures are tested.14,15
These systematically arranged mixtures are utilized since it is, at
best, impractical for any laboratory to screen such large
numbers of individual compounds directly in vivo.
We have previously reported a proof of concept of this
approach by successfully identifying novel individual hetero-
cyclic small molecule opioid analgesics and peptides by utilizing
this mixture-based synthetic combinatorial strategy.16,17 In our
earlier work, the in vivo screening of the positional scanning
library TPI 1955 (a bis-cyclic guanidine library;18 resulted in
the identiﬁcation of two novel opioid analgesics, 1818−101 and
1818−109. These were found to produce antinociception
equivalent to, or better than, morphine without the liabilities of
respiratory depression or conditioned place preference.
Our working hypothesis is that the direct in vivo screening of
systematically arranged small molecule and peptide mixture-
based combinatorial libraries would yield more advanced
therapeutically useful individual compounds possessing favor-
able analgesic properties with decreased side eﬀects. An
important additional value we have found is that novel
antinociceptive compounds that have unknown targets are
also identiﬁed. Using the scaﬀold ranking technique,7 ten
structurally diverse small-molecule combinatorial libraries
included bicyclic guanidines, permethylated polyamines,
diketopiperazines, nitrosamines, phenylureas, cyclic thiazoles,
and cyclic guanidines (Figure 1A) were tested for their
antinociceptive properties in mice. These libraries ranged in
total number from a low of 17 340 to 4 879 681. Each of these
libraries were tested initially as single “all X” mixtures7 in mice
for antinociceptive activity. Two recognized opioid liabilities,
respiratory depression and locomotor activity, were also
monitored.
Applying this strategy in the current study, we used the
scaﬀold ranking technique7 with ten diﬀering libraries in mice.
Ten small-molecule combinatorial libraries were tested in this
Figure 1. (A) Structures of core scaﬀolds for 10 scaﬀold ranking library samples. (B) Synthetic scheme for library 1954 and individual compounds
2213: the starting N-acylated tetrapeptide, 1, is reduced to the linear polyamine by diborane−THF followed by piperidine treatment to disrupt
borane−amine complexes. The next step (b) involved treatment on the resin attached polyamine with oxalyldiimidazole/DMF, to form the bis
diketopiperizone (c). This was then again reduced by diborane to yield the desired bispiperazine (d). This synthesis is described in Nefzi et al.
2009.20 Throughout this manuscript TPI 1954 library samples and 2213 individual compounds have the core scaﬀold shown in the second row, far
left structure. (C) Structures for individual compounds 2213-18, 2213-23, 2213-24, and 2213-54.
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study, TPI 531, 914, 1275, 1952, 1953, 1954, 1481, 1433, 1989,
and 2048 (Figure 1), were tested initially as ten single mixture
samples for both antinociceptive activity and the known opioid
liabilities of respiratory depression and locomotor activity.
The most active of these sample mixtures in analgesic assays
without concordant liabilities, the 1954 series, was then
analyzed using the positional scan approach3−7,19 to determine
the most active antinociceptive functional groups driving the
activity at each of the four positions of this scaﬀold (Figure
4A−D). The 1954 library is built around a core pyrrolidine
bispiperazine scaﬀold (Figure 1) with 26 diﬀerent function-
alities at each of the ﬁrst three diversity positions and 42
functionalities at the fourth position (Figure 4). This results in
a total of 120 mixtures making up this library. Each mixture
varies from 17 576 compounds (position four) to 28 392
(positions 1−3) compounds each, for a total of 738,192
compounds. The most active mixtures in the 120 mixtures
making up library 1954 enabled the identiﬁcation of those
functionalities to be used to synthesize individual compounds
deﬁned in all four positions, termed the 2213 series. Individual
compounds from the 2213-series were compared to morphine
in the mouse 55 °C warm water tail-ﬂick test and also evaluated
for their eﬀects on respiration rate and locomotor activity.
■ RESULTS
Ranking the Ten Scaﬀolds for Antinociceptive
Potency and Potential Liabilities. The scaﬀold ranking
approach was used to determine the optimal library for in depth
screening each scaﬀold was represented by a single mixture
made up of all components of a particular library.7,8,14−16 The
antinociceptive activity of the ten separate “all X” library
scaﬀolds (531, 914, 1275, 1952, 1953, 1954, 1481, 1433, 1989,
and 2048; see Figure 1) were ﬁrst evaluated. Administration of
the ten samples (25 mg/kg, i.p., Figure 2A, red bars)
signiﬁcantly increased the combined time mice required to
remove their tails from a noxious stimulus of 55 °C warm water
(one-way ANOVA F(10,74) = 11.12, p < 0.0001 with Dunnett’s
multiple comparisons post hoc test; red bars, Figure 2A).
Each of these 10 scaﬀolds were then tested at a lower dose (5
mg/kg, Figure 2A, Green Bars). The lower dose screening
reduced the number of samples producing a signiﬁcant
antinociceptive eﬀect response (one-way ANOVA F(10,77) =
10.38, p < 0.0001), with libraries 531, 914, 1952, 1954, and
1989 had signiﬁcant activity (p < 0.05, Dunnett’s multiple
comparisons post hoc test; green bars, Figure 2A). Library 1952
had clear toxicity at 25 mgs/kg, but no toxicity or behavioral
eﬀects at 5 mgs/kg. Also, library 2048 was nominally the most
active, but was found to cause signiﬁcant respiratory depression
(Figure 2B). The respiratory eﬀects found for library 2048 may
be associated with mu opiate activity and will be evaluated in a
separate study.
Of the remaining scaﬀold samples (1275, 1954, and 1989),
the sample representing the 1954 library produced the greatest
magnitude of antinociceptive activity (one-way ANOVA F(2,21)
= 3.41, p = 0.05), establishing this scaﬀold for further evaluation
in the current study. Nonparametric bootstrapping analysis37
conﬁrmed that the 1954 samples were unlikely to exhibit
hyperlocomotion (a 32% chance) or respiratory depression (a
30% chance), and second most likely to be more active than
morphine (at 5 mg/kg, i.p.; Figure 3).
In Vivo Positional Scanning of the 1954 Series
Library. Utilizing the positional scanning approach,4,19 the
antinociceptive activity of each of the 120 mixture-based
samples comprising the 1954 series library was evaluated after
administration (5 mg/kg, i.p.) with the 55 °C warm-water tail-
withdrawal assay (Figure 4). The combined time mice
demonstrated to withdraw their tail was summed over the
seven time points examined for each sample tested and is
reported by substitution position (Figure 4A−D). Notably, a
number of samples deﬁned at each substitution position
increased the combined time for tail withdrawal.
Nonparametric probabilistic analysis was also performed for
each sample in the full positional scanning format. This
predicted the likelihood of a given mixture containing
functionalities that would be more active than the scaﬀold
alone (Figure 5). Levels of probability values varied from
position to position; two samples in R2 had a greater than 50%
chance of exceeding the activity of an all X sample (Figure 5B),
while 11, 14, and 27 were above 50% in positions R1, R3, and
R4, respectively (Figure 5A, C, and D). Although this analysis
generally mirrored the relative numbers of elevated results
described at each position in the antinociceptive testing,
probability rank ordering at each position varied slightly from
median rank ordering, indicating some asymmetric variability to
Figure 2. Scaﬀold ranking of libraries 531, 914, 1275, 1952, 1953, 1954, 1481, 1433, 1989, and 2048. (A) Screening by in vivo of antinociception
response in the mouse 55 °C warm water tail-withdrawal test. All mixture-based samples were administered at a dose of 5 mg/kg, i.p. (green bars)
and 25 mg/kg i.p. (red bars). For structures of the libraries see Figure 1. Response to vehicle (10% DMSO, i.p.) represented as dashed line; dotted
lines represent SEM. Data represent average (±SEM) summed tail-withdrawal latencies calculated by taking the sum of the average tail withdrawal
latencies for each animal from each time point over a 24-h period. Bars =7−8 mice each. B: Screening by respiration response. All mixture-based
samples were administered at a dose of 5 mg/kg, i.p.; vehicle (10% DMSO, i.p.) was administered as a control. Data represent average (±SEM)
respiration rate (in breaths per minute, BPM) over a 90 min period. Bars =8 mice each, except vehicle, which was 40 mice. *Signiﬁcantly diﬀerent
from response to vehicle, p < 0.05, one-way ANOVA followed by Dunnett’s post hoc test.
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some of the data points that the probabilistic analysis was able
to take into account. On the basis of these data, optimal
substitution groups for each position were selected to construct
individual compounds. Natural gaps in the probability values
indicated the selection of four functionalities for the R1 position
(S-2-naphthylmethyl, R-2-naphthylmethyl, R-hydroxymethyl,
and S-butyl), S-cyclohexyl for the R2 position, and four
functionalities each for the R3 position (R-4-hydroxybenzyl, R-
2-butyl, (S,R)-1-hydroxyethyl, and R-butyl) and R4 position (3-
cyclopentyl-propyl, 3,4-dichlorophenethyl, 2-adamantan-1-yl-
ethyl, and 4-tert-butyl-cyclohexyl-methyl). To reduce the
number of individual compounds tested, structurally redundant
choices with lower activity were eliminated. Moreover, to
increase structural diversity in the R2 position, the next most
active functionality (R-2-naphthylmethyl) was added. The ﬁnal
choices were then combined to synthesize 54 (3 × 2 × 3 × 3)
individual, fully deﬁned compounds; the TPI 2213 series
(Table 1).
Testing of Individual 2213 Compounds. Ranking the
54 Individual 2213-Series Compounds for Antinociceptive
Potency. To prioritize the samples to be evaluated in detail,
each of the 54 compounds in the 2213 series (10 mg/kg, i.p.)
was tested for analgesic activity. The combined time mice
demonstrated to withdraw their tail was summed over the
seven time points examined for each compound tested (Table 1
and Figure 6). Although the majority of samples produced
signiﬁcant antinociception as compared to baseline tail-
withdrawal responses (one-way ANOVA, F(55,408) = 15.6, p <
0.0001; Tukey’s Multiple comparison post hoc test), seven of
these individual samples produced antinociception equivalent
to that of morphine (P > 0.05, not signiﬁcantly diﬀerent;
Tukey’s Multiple comparison post hoc test): 2213-12, -17, -18,
-20, -21, -24, and -32. Accordingly, these compounds were
selected for detailed characterization. Moreover, as compound
2213-23 is a single position analog of 2213-24 (at the R4
Figure 3. Nonparametric probability analysis of scaﬀold-ranking
library results to select the speciﬁc library for positional scanning.
Figure 4. Positional scan screening of 1954-series OXXX samples: summed antinociception produced by 1954 series samples measured in the mouse
55 °C warm water tail-withdrawal test across a 24-h period. (A) 1954 deﬁned at position 1 (gray bars). (B) 1954 deﬁned at position 2 (green bars).
(C) 1954 deﬁned at position 3 (red bars). (D) 1954 deﬁned at position 4 (blue bars). The combined time to withdraw tails (s; y-axis) was calculated
by taking the sum of the average tail-withdrawal latencies from each time point. Samples (x-axis; see Table 2 below for full identities of the various
chosen for the individual compounds prepared) were administered at a dose of 5 mg/kg i.p. for testing. Functionalities of key samples are described
in simpliﬁed form for convenience; see Table 1 for complete descriptions. Data represent average (±SEM) summed tail-withdrawal latencies
calculated by taking the sum of the average tail-withdrawal latencies for each animal from each time point over a 24-h period. Samples administered
at dose of 5 mg/kg, i.p. Bars = 8 mice each.
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position) and 2213-32 (at the R2 position), and compound
2213-54 is a single position analog of 2213-18 (R1 position),
2213-23, and 2213-54, these were further examined (Figure 7).
The nine individual analogs that produced the greatest
antinociceptive activity were selected for more detailed
antinociceptive characterization in vivo. The Structures of
these compounds are shown in Supporting Information Figure
1. Like morphine, each of the selected individual analogs
exhibited antinociceptive activity in vivo, albeit with varying
potencies (Table 2). All nine 2213-series compounds produced
maximal antinociception 30 min after i.p. administration of each
dose tested, returning to baseline levels 3 h after administration
of the maximal dose tested (10 mg/kg, i.p.). Signiﬁcant
diﬀerences in potency were demonstrated by comparison of the
shift in ED50 values by nonlinear regression modeling (F(8,235) =
14.95; P < 0.0001; Figure 7).
Opioid receptor selectivity in vivo of each 2213-series
compound after i.p. administration was determined by
pretreating mice with selective opioid receptor antagonists
prior to testing in the 55 °C warm water tail-withdrawal assay as
shown in Figure 8. Opioid receptor antagonists were
administered at doses and in suﬃcient advance of TPI
compounds to ensure inhibition of only one type of opioid
receptor. Additionally, mice lacking the MOR demonstrated
signiﬁcant reductions in the eﬀect of TPI 2213−18, −23, −24,
and −54. In contrast, pretreatment of wild-type mice with the
KOR-selective antagonist nor-BNI or the DOR-selective
antagonist naltrindole variably reduced antinociception pro-
duced by the nine diﬀerent 2213-samples tested (Figure 8).
These results suggest that the diﬀering substitutions in the 2213
series samples resulted in diﬀering responses to the three opioid
receptors. Interestingly none of the compounds exhibited Ki
Figure 5. Nonparametric mathematical analysis of 1954-library positional scanning screening results used to select speciﬁc residues deﬁning the
2213-series library of individual compounds at the R1 position (A), the R2 position (B), the R3 position (C), and the R4 position (D). Probability
values were rank ordered and compared to obtained signiﬁcances to conﬁrm that there were no substantial discrepancies.
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values less than 1 μM (Supporting Information Table 1) at any
of the three opioid receptors when tested in vitro.
The eﬀects of the selected TPI-2213 compounds on
respiration rate and both spontaneous and evoked locomotor
activity were assessed. Mice were administered TPI-2213
compounds at twice the ED50 dose calculated from
antinociceptive dose−response testing, or roughly correspond-
ing to a maximal antinociceptive eﬀect. Additional mice were
treated with vehicle (10% DMSO in 0.9% sterile saline, i.p.) or
morphine (10 mg/kg, i.p.) for comparison.
Table 1. Individual TPI-2213 Series Compounds Synthesized
ID R1 R2 R3 R4
2213-1 S-2-naphthyl methyl S-cyclohexyl R-4-hydroxybenzyl 3-cyclopentyl-propyl
2213-2 S-2-naphthyl methyl S-cyclohexyl R-4-hydroxybenzyl 3,4-dichlorophenethyl
2213-3 S-2-naphthyl methyl S-cyclohexyl R-4-hydroxybenzyl 2-adamantan-1-yl-ethyl
2213-4 S-2-naphthyl methyl S-cyclohexyl R-2-butyl 3-cyclopentyl-propyl
2213-5 S-2-naphthyl methyl S-cyclohexyl R-2-butyl 3,4-dichlorophenethyl
2213-6 S-2-naphthyl methyl S-cyclohexyl R-2-butyl 2-adamantan-1-yl-ethyl
2213-7 S-2-naphthyl methyl S-cyclohexyl (S,R)-1-hydroxyethyl 3-cyclopentyl-propyl
2213-8 S-2-naphthyl methyl S-cyclohexyl (S,R)-1-hydroxyethyl 3,4-dichlorophenethyl
2213-9 S-2-naphthyl methyl S-cyclohexyl (S,R)-1-hydroxyethyl 2-adamantan-1-yl-ethyl
2213-10 S-2-naphthyl methyl R-2-naphthylmethyl R-4-hydroxybenzyl 3-cyclopentyl-propyl
2213-11 S-2-naphthyl methyl R-2-naphthylmethyl R-4-hydroxybenzyl 3,4-dichlorophenethyl
2213-12 S-2-naphthyl methyl R-2-naphthylmethyl R-4-hydroxybenzyl 2-adamantan-1-yl-ethyl
2213-13 S-2-naphthyl methyl R-2-naphthylmethyl R-2-butyl 3-cyclopentyl-propyl
2213-14 S-2-naphthyl methyl R-2-naphthylmethyl R-2-butyl 3,4-dichlorophenethyl
2213-15 S-2-naphthyl methyl R-2-naphthylmethyl R-2-butyl 2-adamantan-1-yl-ethyl
2213-16 S-2-naphthyl methyl R-2-naphthylmethyl (S,R)-1-hydroxyethyl 3-cyclopentyl-propyl
2213-17 S-2-naphthyl methyl R-2-naphthylmethyl (S,R)-1-hydroxyethyl 3,4-dichlorophenethyl
2213-18 S-2-naphthyl methyl R-2-naphthylmethyl (S,R)-1-hydroxyethyl 2-adamantan-1-yl-ethyl
2213-19 R-hydroxymethyl S-cyclohexyl R-4-hydroxybenzyl 3-cyclopentyl-propyl
2213-20 R-hydroxymethyl S-cyclohexyl R-4-hydroxybenzyl 3,4-dichlorophenethyl
2213-21 R-hydroxymethyl S-cyclohexyl R-4-hydroxybenzyl 2-adamantan-1-yl-ethyl
2213-22 R-hydroxymethyl S-cyclohexyl R-2-butyl 3-cyclopentyl-propyl
2213-23 R-hydroxymethyl S-cyclohexyl R-2-butyl 3,4-dichlorophenethyl
2213-24 R-hydroxymethyl S-cyclohexyl R-2-butyl 2-adamantan-1-yl-ethyl
2213-25 R-hydroxymethyl S-cyclohexyl (S,R)-1-hydroxyethyl 3-cyclopentyl-propyl
2213-26 R-hydroxymethyl S-cyclohexyl (S,R)-1-hydroxyethyl 3,4-dichlorophenethyl
2213-27 R-hydroxymethyl S-cyclohexyl (S,R)-1-hydroxyethyl 2-adamantan-1-yl-ethyl
2213-28 R-hydroxymethyl R-2-naphthylmethyl R-4-hydroxybenzyl 3-cyclopentyl-propyl
2213-29 R-hydroxymethyl R-2-naphthylmethyl R-4-hydroxybenzyl 3,4-dichlorophenethyl
2213-30 R-hydroxymethyl R-2-naphthylmethyl R-4-hydroxybenzyl 2-adamantan-1-yl-ethyl
2213-31 R-hydroxymethyl R-2-naphthylmethyl R-2-butyl 3-cyclopentyl-propyl
2213-32 R-hydroxymethyl R-2-naphthylmethyl R-2-butyl 3,4-dichlorophenethyl
2213-33 R-hydroxymethyl R-2-naphthylmethyl R-2-butyl 2-adamantan-1-yl-ethyl
2213-34 R-hydroxymethyl R-2-naphthylmethyl (S,R)-1-hydroxyethyl 3-cyclopentyl-propyl
2213-35 R-hydroxymethyl R-2-naphthylmethyl (S,R)-1-hydroxyethyl 3,4-dichlorophenethyl
2213-36 R-hydroxymethyl R-2-naphthylmethyl (S,R)-1-hydroxyethyl 2-adamantan-1-yl-ethyl
2213-37 S-butyl S-cyclohexyl R-4-hydroxybenzyl 3-cyclopentyl-propyl
2213-38 S-butyl S-cyclohexyl R-4-hydroxybenzyl 3,4-dichlorophenethyl
2213-39 S-butyl S-cyclohexyl R-4-hydroxybenzyl 2-adamantan-1-yl-ethyl
2213-40 S-butyl S-cyclohexyl R-2-butyl 3-cyclopentyl-propyl
2213-41 S-butyl S-cyclohexyl R-2-butyl 3,4-dichlorophenethyl
2213-42 S-butyl S-cyclohexyl R-2-butyl 2-adamantan-1-yl-ethyl
2213-43 S-butyl S-cyclohexyl (S,R)-1-hydroxyethyl 3-cyclopentyl-propyl
2213-44 S-butyl S-cyclohexyl (S,R)-1-hydroxyethyl 3,4-dichlorophenethyl
2213-45 S-butyl S-cyclohexyl (S,R)-1-hydroxyethyl 2-adamantan-1-yl-ethyl
2213-46 S-butyl R-2-naphthylmethyl R-4-hydroxybenzyl 3-cyclopentyl-propyl
2213-47 S-butyl R-2-naphthylmethyl R-4-hydroxybenzyl 3,4-dichlorophenethyl
2213-46 S-butyl R-2-naphthylmethyl R-4-hydroxybenzyl 2-adamantan-1-yl-ethyl
2213-49 S-butyl R-2-naphthylmethyl R-2-butyl 3-cyclopentyl-propyl
2213-50 S-butyl R-2-naphthylmethyl R-2-butyl 3,4-dichlorophenethyl
2213-51 S-butyl R-2-naphthylmethyl R-2-butyl 2-adamantan-1-yl-ethyl
2213-52 S-butyl R-2-naphthylmethyl (S,R)-1-hydroxyethyl 3-cyclopentyl-propyl
2213-53 S-butyl R-2-naphthylmethyl (S,R)-1-hydroxyethyl 3,4-dichlorophenethyl
2213-54 S-butyl R-2-naphthylmethyl (S,R)-1-hydroxyethyl 2-adamantan-1-yl-ethyl
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Morphine depressed respiration 22% (Figure 9A), and
induced spontaneous ambulatory activity 7.5-fold as compared
to the responses of saline-treated animals (Figure 9B). Many of
the TPI 2213-lead compounds also signiﬁcantly induced
respiratory depression (F(10,113) = 7.48, p < 0.0001; Figure
9A), however 2213-17, 2213-20, and 2213-32 did not
signiﬁcantly alter breathing rate at this screening dose (p >
0.05; Dunnett’s post hoc test). Likewise, the three compounds
did not signiﬁcantly impact spontaneous ambulatory activity at
this same dose, whereas the other TPI 2213 lead compounds
produced hypolocomotion (F(9,102) = 4.03, p = 0.0002, with
Dunnett’s post hoc test excluding morphine; Figure 9B).
Locomotor activity, examined with the rotorod assay following
treatment with eight of TPI 2213 lead compounds at their
ED50×2 dose indicated mild sedation by several of the
compounds, although this was only signiﬁcant with TPI
2213-20 and TPI 2213-32 (Figure 9C).
■ DISCUSSION
Two primary approaches are used to prepare and screen large
numbers of compounds. These are (1) the massive parallel
synthesis and robotic screening of large individual compound
arrays and (2) the generation and screening of extremely large
systemtically formatted mixture-based libraries. Once individual
compounds are identiﬁed as therapeutically useful, their general
target activities are improved by classic medicinal chemistry
structure−activity relationship approaches prior to testing in
vivo. However, it remains highly impractical for the majority of
academic and small research organizations to make and screen
such large numbers of compounds as individuals and can be in
many cases prohibitively expensive as well. The large synthetic
mixture based libraries utilized in thus current study were made
using the solid phase parallel approach commonly known as the
“tea bag” approach.21 Mixture-based combinatorial libraries
made up of 10s of thousands to millions of compounds were
used in the current studies.4,6,10−12,20 The scaﬀold ranking
approach7,11,16,17 was used to identify a promising scaﬀold,
followed by a full positional scanning screen of the pyrrolidine
bis-piperazines library (library number 1954). Consistent with
previous demonstrations of use mixture based libraries directly
in vivo7,8,11,16,17 the deconvolution of the 1954-library data
resulted in the subsequent identiﬁcation of a series of 54
individual compounds, eight of which proved equi-analgesic to
morphine.
It is notable that the vast majority of novel compounds
initially found to be promising are rejected at the in vivo stage
of the drug discovery process.2,22−24 To circumvent the
limitations of existing in vitro screening methods, we are able
to test samples from our mixture-based combinatorial libraries
directly in vivo for analgesic properties. When successful, this
approach can be expected to enable the evaluation of very large
Figure 6. Screening of individually deﬁned compounds using in vivo antinociception: summed antinociception produced by 2213 series samples (10
mg/kg, i.p.) measured in the mouse 55 °C warm water tail-withdrawal test across a 8-h testing period. Vehicle eﬀects (dashed horizontal line)and
morphine (10 mg/kg, i.p., far right bar) as a positive control. Data represent average (±SEM) summed tail-withdrawal latencies Bars = 8 mice each.
*Signiﬁcantly greater than vehicle eﬀect, p < 0.05, but not morphine; one-way ANOVA followed by Tukey Multiple comparison test.
Figure 7. Dose-dependent antinociception produced by selected TPI-
2213 series compounds. Dose−response lines of morphine and TPI-
2213-12, -17, -18, -20, -21, -23, -24, -32, and -54 given by i.p. injection
30 min prior to testing in the mouse 55 °C warm water tail-withdrawal
assay. Points = 8 mice each. On the basis of the ED50 (and 95%
conﬁdence interval) values (Table 2), each 2213 compound exhibited
similar antinociceptive potencies to morphine, with the exception of
2213-54, which displayed approximately half the potency of morphine.
Table 2. Antinociceptive Activity of Morphine and 9
Individual Selected Compounds from the TPI-2213 Seriesa
Compound ED50 and 95%C.I. (mg/kg, i.p.)
Morphine 2.48 (1.63−3.51)
2213−12 3.41 (2.93−3.98)
2213−17 2.81 (2.11−3.69)
2213−18 2.30 (1.72−2.95)
2213−20 2.10 (1.52−2.72)
2213-21 2.36 (1.83−2.96)
2213−23 3.73 (3.04−4.65)
2213−24 3.43 (2.79−4.25)
2213−32 3.03 (2.49−3.68)
2213−54 5.72 (4.29−8.36)
aMice (n = 24) were administered a graded dose of morphine (as a
positive control) or the TPI-2213 compound (i.p.) and tested in the
55°C warm-water tail-withdrawal assay 30 min later. ED50 and 95%
conﬁdence interval values (in mg/kg) are reported.
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numbers of compounds while decreasing the failure rate
inherent in the typical drug discovery process. Thus, the direct
in vivo screening of mixture-based samples enables millions of
acyclic and heterocyclic small molecules to be screened in
animal models of disease. This would not be practical if one
were to test even a fraction of the compounds screened in the
present study. The outcome of this “high-throughput in vivo
screening” process resulted in the early identiﬁcation of
favorable lead compounds with demonstrable and clear in
vivo activity. These were more advanced in the drug discovery
eﬀort than the traditional HTS of individual compounds
identiﬁed using in vitro processes. Many elements drive the
value of this approach, including the inherent SAR data
obtained directly from the initial positional scanning
information set as well as the ability to identify hit or lead
Figure 8. Opioid receptor selectivity of selected TPI-2213 series compounds. Bars = 8 mice each. TPI-2213 compounds administered i.p. at ED90
dose (or higher) in MOR KO mice (striped bars) or wild-type mice with or without pretreatment with nor-BNI (10 mg/kg, i.p., − 24 h; criss crossed
or naltrindole (20 mg/kg, i.p., −20 min, dotted bars). 2213-54 was tested in KOR KO mice instead of wild-type mice pretreated with nor-BNI.
Antinociception was measured 30 min after administration of the TPI-2213 compound. * = Signiﬁcantly diﬀerent from baseline latency. † =
Signiﬁcantly less than matching 2213 compound alone, p < 0.05.
Figure 9. Liability screening of selected TPI-2213 individual compounds. Individual 2213-compounds were administered i.p. at an ED50×2 dose (see
Table 2); vehicle (10% DMSO, i.p.) and morphine (10 mg/kg, i.p.) were administered as controls. (A) Respiration response. Data represent average
(±SEM) respiration rate (in breaths per minute, BPM) over a 50 min period. (B) Spontaneous locomotor response. Data represent average
(±SEM) ambulation rate (in crossing ambulations per minute, XAMB) over a 50 min period. (C) Evoked locomotor response on rotorod (indicated
by latency to fall from a rotorod as the percent change from baseline performance/10 min) of mice. Bars = 8 mice each, except vehicle (40 mice) and
morphine (24 mice). Points = 8 mice each, except vehicle (which was 16 mice). *Signiﬁcantly diﬀerent from response to vehicle, p < 0.05, one-way
ANOVA followed by Dunnett’s post hoc test.
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compounds to unknown targets that would not be identiﬁed
through traditional HTS.
Compounds identiﬁed using in vivo HTS can act via (1) a
single, known target, (2) multiple, known targets providing the
overall eﬀect, or (3) unknown target(s). Such studies can
potentially lead to the identiﬁcation of new biological targets
and/or pathways for therapeutic intervention. The approach
also identiﬁes structurally novel compounds and is able to
quickly detect potential problems (such as acute in vivo
toxicity) that would not typically be recognized by traditional
drug discovery approaches until much later in the drug
discovery process. In vivo HTS is led completely by the overall
activity of the compounds in the animal model utilized with no
preconceived bias for the mechanism of action. Additionally, by
screening directly in vivo, many drug development issues are
addressed very early on, such as pharmacokinetics, blood-brain
barrier penetration, and even bioavailability (if oral dosing is
utilized). The overall in vivo HTS method allows for testing of
many of these potential issues upon ﬁrst testing the libraries.
The current ﬁndings add to a growing body of work proving
both the feasibility and utility of this approach. Previous
screening by monitoring blood pressure and heart rate in rats
after administration of 400 separate mixtures each of 130 321
hexapeptides using an iterative versus the current positional
scanning approach11 identiﬁed possible development candi-
dates while simultaneously eliminating compounds with poor
absorption, distribution, metabolism, and pharmacokinetic
properties.
While the end result of the present search for low-liability
analgesic agents was successful, additional detailed screening of
libraries based on other scaﬀolds can be expected to provide
additional enhanced antinociceptive agents. It should be noted
that the identiﬁcation of selective, novel opioid receptor
antagonists is of potential therapeutic value. While not within
the scope of the present study, the lack of antinociceptive
response from select mixture samples in the 1954 library
suggests the possibility of the presence potential antagonists
using this approach. It is notable that opioid receptor
antagonists have been identiﬁed from positional scanning and
screening of synthetic peptide combinatorial libraries.25
In addition to using average or median values to rank-order
scaﬀolds and positional scanning mixtures, an additional
nonparametric conﬁrmatory process was performed. Probability
rank ordering at each position varied slightly from traditional
median rank ordering, an indication of little asymmetric
variability in the data, the probabilistic analysis was able to
account for this eﬀect and predict potentially useful
functionality groups. On the basis of these analyses, the
substitution groups for each position yielded conﬁdence in the
selection of active individual compounds. The implementation
of nonparametric analysis increases the likelihood of success
with the deconvolution process, as well as the use of
combinatorial libraries themselves. In practical terms what
this means is that one would not expect multiexponential
increases in activity as we move from the all-X mixture, to the
positional scanning libraries, to the individual compounds. In
practice, because of the systematic formatting of the libraries
one would typically anticipate steady increases in activity as the
complexity of the mixtures is reduced. This was what was in fact
found in the current study.
An exciting aspect of the present data stems from the
promising in vivo activity of TPI 2213-17 (despite poor opioid
receptor aﬃnity demonstrated by in vitro mu, delta, and kappa
RRA opiate testing). Results of this nature might otherwise
have halted further examination of these compounds. A
mechanism of action for the activity found in vivo is unclear
at this juncture. It is possible that the activity is due to
nonopioid-mediated interactions induced by the TPI com-
pounds. Although the reduction (or, in other samples,
elimination) of antinociception by pretreatment with opioid-
receptor selective antagonists and/or testing in opioid receptor
knock out mice strongly appears to implicate at least a partial
opioid-receptor mediation of antinociception, there is prece-
dence for clinical analgesics to work through a combination of
opioid and nonopioid sites to alleviate pain. For example,
tramadol mediates antinociception. through a combination of
opioid and nonopioid (inhibition of monoamine uptake)
mechanisms26 Further study of the interaction of the TPI-
2213 compounds with other targets such as TRPV-1 or
monoamine transporters are planned in the future.
It also remains possible that the in vivo antinociception
observed may be attributed to a metabolite of the lead TPI-
2213 compounds tested. As these metabolites would not be
produced while utilizing an in vitro assay, potential metabolites
could account for the opioid receptor activity, not unlike
morphine-6β-glucuronide demonstrating higher potency at the
MOR receptor over that of the parent substrate, morphine,27 or
metabolites of tramadol.28,29 Alternatively, it is also possible
that the administration of the 2213-series compounds induce
the release of an endogenous opioid, such as β-endorphin or an
enkephalin. A number of compounds have been shown to
induce the release of endorphins resulting in opioid-receptor-
mediated antinociception, including the endothelin A receptor
antagonist BQ-12330 and agonists of endothelin B receptors.31
However, as the endogenous opioids produce all the
detrimental eﬀects of opioid agonists such as the respiratory
depression induced by β-endorphin,32 it is unclear why TPI
2213-17 would produce opioid mediated antinociception
without the opioid-mediated liabilities such as sedation typically
attributed to activation of the kappa opioid receptor. A simpler
alternative explanation may be that TPI 2213-17, -20, or -32
poorly penetrate the central nervous system following
peripheral administration, thereby restricting the activity of
these compounds to the periphery after intraperitoneal
administration. Peripherally restricted opioid agonists such as
N-methylmorphine have been shown to produce relief from
some types of pain33,34 and could provide opioid analgesia with
fewer liabilities of use, as they would be expected to lack many
of the detrimental clinical eﬀects mediated by mechanisms in
the CNS.35 Though clearly important, the precise mechanism
mediating the eﬀects of the 2213-series compounds, is beyond
the scope of this initial screening study. With speciﬁc
compounds now identiﬁed, additional future work will further
elucidate their mechanism of action.
In conclusion, the in vivo screening scaﬀold-based library
samples tested directly in a mouse model directed us to use a
positional scanning approach to screen the 120 mixture samples
making up library 1954, which comprised in total 738 192
compounds. The results yielded diﬀerentially active mixtures at
each position that produced robust antinociception in the 55
°C warm water tail-withdrawal assay. The most active
functionalities associated with each diversity position on the
1954 scaﬀold yielded the information necessary for the
synthesis of 54 individual compounds, termed the TPI 2213
series. The most active of these compounds produced a dose-
dependent antinociception equivalent to morphine that was
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blocked by opioid-receptor selective antagonists. Importantly,
TPI 2213-17 emerged from these compounds without causing
respiratory depression or locomotor eﬀects at therapeutically
maximal doses, suggesting this may produce analgesia without
the clinical liabilities presented by morphine. Beyond this, the
results demonstrate the validity of using scaﬀold ranking of
mixture-based combinatorial libraries and deconvolution by the
use of the positional scanning approach following the in vivo
testing results. This enabled the rapid identiﬁcation of active
individual compounds with enhanced potential therapeutic
value and lower liabilities of use.
■ EXPERIMENTAL PROCEDURES
Synthesis of the Scaﬀold Libraries. The scaﬀold ranking
library contains one sample representing each of the positional
scanning libraries and these are termed all “X libraries” in that
no speciﬁc position is individually deﬁned (Figure 1B). Each
sample contains an approximately equal molar amount of every
compound in that library. For example, the sample 1954 in the
scaﬀold ranking library contains 738 192 compounds in
approximately equal molar amounts. These samples were
prepared by mixing the cleaved products of the complete
positional scanning library, or by directly synthesizing the
sample as a single mixture as was the case for sample
1954.7,8,15,16
Synthesis of the TPI 1954 Library. TPI 1954 is a
positional scanning library comprised of 738 192 pyrrolidine
bis-piperazines (Figure 1; for a list of the functionalities at each
of the four substitution sites, see Figure 4). The R1 through R3
functionalities are derived from 26 amino acids (Figure 4A−C
and Figure 5A−C) and the R4 functionalities are derived from
42 carboxylic acids (Figures 4D and 5D) such that the library
contains 738 192 (26 × 26 × 26 × 42) compounds
systematically arranged into 120 (26 + 26 + 26 + 42) mixture
samples. The synthesis of the pyrrolidine bis-piperazine library,
1954, is described in Figure 1 and elsewhere.18 Brieﬂy, the ﬁrst
26 samples (Figures 4A and 5A) permit the assessment of the
activity of the 26 diﬀerent functionalities used at the R1
position. In these 26 mixtures, each of the samples has a
ﬁxed functionality at the R1 position and an equal molar
mixture of the 26 functionalities at R2 (Figure 5B), 26
functionalities at R3 (Figure 5C), and 42 functionalities at R4
(Figure 5D). For example, sample 1 contains an equal molar
mixture of 28,392 (26 × 26 × 42) compounds all ﬁxed with S-
methyl at the R1 position, whereas sample 2 contains an equal
molar mixture of 28 392 compounds all ﬁxed with S-benzyl at
the R1 position. In this way, samples 1 to 26 scan the ﬁrst
position by ﬁxing each of the 26 samples with a diﬀerent
functionality at the R1 position. The next 26 samples (samples
27 to 52) assess the functionalities at R2 by ﬁxing the R2
position and having equal molar mixtures at the other three
positions. Likewise, samples 53 to 78 assess the R3
functionalities, and samples 79 to 120 assess the R4
functionalities.
Synthesis of the 2213 Individual Compounds. The
synthesis of the 54 individual compounds comprising the TPI
2213-series (Table 1) utilizes the synthetic scheme described in
Figure 1. The solid-phase synthesis was performed using the
tea-bag methodology.21 The synthesis of the pyrollidine bis
piperazines was carried out as described earlier.18 Initially, 100
mg of p-methylbenzdrylamine (MBHA) resin (1.1 mmol/g,
100−200 mesh) was sealed in a mesh “tea-bag,” neutralized
with 5% diisopropylethylamine (DIEA) in dichloromethane
(DCM), and subsequently swelled with additional DCM
washes. Boc-amino acids (R1, L-proline, R2, and R3) were
coupled utilizing standard coupling procedures (6 equiv) with
DIC (6 equiv) and HOBt (6 equiv) in DMF (0.1M) for 120
min. All coupling reactions are monitored for completion by
the ninhydrin test. After each coupling the Boc protecting
group was removed with 55% triﬂuoroacetic Acid (TFA) in
DCM for 30 min and subsequently neutralized with 5% DIEA/
DCM (3×). Ten equivalents of carboxylic acids (R4) were
coupled using 10 equiv of each carboxylic acid in the presence
of DIC (10 equiv) and HOBt (10 equiv) in DMF (0.1M) for
120 min (1, Figure 1). The reduction was performed in a 4000
mL Wilmad LabGlass vessel under nitrogen. A standard borane
in 1.0 M Tetrahydrofuran complex solution was used in 40 fold
excess for each amide bond. The vessel was heated to 65 °C
and maintained at temperature for 72 h. The solution is then
discarded and the bags are washed with THF and methanol.
Once completely dry, the bags are treated overnight with
piperidine at 65 °C and washed several times with methanol,
DMF, and DCM (2, Figure 1). Before proceeding, completion
of reduction is monitored by a control cleavage and analyzed by
LCMS. Diketopiperazine cyclization (3, Figure 1) was
performed with a 5 fold excess of oxalyldiimidazole in a 0.1
M anhydrous DMF solution for each of the cyclization sites
overnight. Following the cyclization, the bags are rinsed with
DMF and DCM. Before proceeding, completion of cyclization
is monitored by a control cleavage and analyzed by LCMS. The
reduction (4, Figure 1) was performed in a 4000 mL Wilmad
LabGlass vessel under nitrogen. A 1.0 M Tetrahydrofuran/
borane complex solution was used in 40-fold excess for each
amide bond. The vessel is heated to 65 °C and maintained at
temperature for 72 h. The solution is then discarded and the
bags are washed with THF and methanol. Once completely dry,
the bags are treated overnight with piperidine at 65 °C and
washed several times with methanol, DMF and DCM. The
resin is cleaved with HF in the presence of anisole in an ice
bath at 0 °C for 7 h (5, Figure 1).
LCMS Analysis. The purity and identity of all compounds
was veriﬁed using a Shimadzu 2010 LCMS system, consisting
of a LC-20AD binary solvent pumps, a DGU-20A degasser unit,
a CTO-20A column oven, and a SIL-20A HT auto sampler. A
Shimadzu SPD-M20A diode array detector was used for
detections. A full spectra range of 190−600 nm was obtained
during analysis. Chromatographic separations were obtained
using a Phenomenex Luna C18 analytical column (5 μm, 50 ×
4.6 mm i.d.) The column was protected by a Phenomenex C18
column guard (5 μm, 4 × 3.0 mm i.d.). All equipment was
controlled and integrated by Shimadzu LCMS solutions
software version 3. Mobile phases for LCMS analysis were
HPLC grade or LCMS grade obtained from Sigma-Aldrich and
Fisher Scientiﬁc. The mobile phases consisted of a mixture
LCMS grade Acetonitrile/water (both with 0.1% formic acid
for a pH of 2.7). The initial setting for analysis was set at 5%
acetonitrile (v/v), then was linearly increased to 95%
acetonitrile over 6 min. The gradient was then held at 95%
acetonitrile for 2 min and then linearly decreased to 5% over
0.10 min and held until stop for an additional 1.90 min. The
total run time was equal to 12 min. The total ﬂow rate was set
to 0.5 mL/min. The column oven and ﬂow cell temperature for
the diode array detector was set at 30 °C. The auto sampler
temperature was held at 15 °C. 5uL was injected for analysis.
HPLC Puriﬁcation. Compound puriﬁcation was performed
on a Shimadzu Prominence preparative HPLC system,
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consisting of LC-8A binary solvent pumps, a SCL-10A system
controller, a SIL-10AP auto sampler, and a FRC-10A fraction
collector. A Shimadzu SPD-20A UV detector was used for
detection. The wavelength was set at 214 nm during analysis.
Chromatographic separations were obtained using a Phenom-
enex Luna C18 preparative column (5 μm, 150 × 21.5 mm
i.d.). The column was protected by a Phenomenex C18 column
guard (5 μm, 15 × 21.2 mm i.d.). Prominence prep software
was used to set all detection and collection parameters. The
mobile phases for HPLC puriﬁcation were HPLC grade
obtained from Sigma-Aldrich and Fisher Scientiﬁc. The mobile
phase consisted of a mixture of Acetonitrile/water (both with
0.1% formic acid). The initial setting for separation was set at
2% Acetonitrile, which was held for 2 min, then the gradient
was linearly increased to 20% Acetonitrile over 4 min. The
gradient was then linearly increased to 55% Acetonitrile over 36
min. The HPLC system was set to automatically ﬂush and re-
equilibrate the column after each run for a total of 4 column
volumes. The total ﬂow rate was set to 12 mL/min and the
total injection volume was set to 3900 μL. The fraction
collector was set to collect from 6 to 40 min. The
corresponding fractions were then combined and lyophilized.
Key Compounds. 4-(((R)-1-(2-(Adamantan-1-yl)ethyl)-4-
((R)-1-(naphthalen-2-yl)-3-((S)-2-(((S)-2-(naphthalen-2-
ylmethyl)piperazin-1-yl)methyl)pyrrolidin-1-yl)propan-2-yl)-
piperazin-2-yl)methyl)phenol (12). Using the synthetic
approach described in Figure 1 for the synthesis of
pyrrolidine-bis-piperazines compound 12 was synthesized
using the following reagents: Boc-L-2-naphthylalanine (R1),
Boc-D-2-naphthylalanine (R2), Boc-D-tyrosine (2-Br-Z)-OH
(R3), and 1-adamantaneacetic acid (R4). Final crude product
was puriﬁed by HPLC as described above. LCMS (ESI+) Calcd
for C56H71N5O: 830.57, found [M + H]+: 830.30. LCMS
retention time (214 nm): 3.73
(R)-1-((S)-1-(3,4-Dichlorophenethyl)-4-((R)-1-(naphthalen-
2-yl)-3-((S)-2-(((S)-2-(naphthalen-2-ylmethyl)piperazin-1-yl)-
methyl)pyrrolidin-1-yl)propan-2-yl)piperazin-2-yl)ethanol
(17). Using the synthetic approach described in Figure 1 for the
synthesis of pyrrolidine-bis-piperazines compound 17 was
synthesized using the following reagents: Boc-L-2-naphthylala-
nine (R1), Boc-D-2-naphthylalanine (R2), Boc-D-threonine
(Bzl)-OH (R3), and 3,4-dichlorophenylacetic acid (R4).
LCMS (ESI+) Calcd for C47H57Cl2N5O: 778.40, found [M +
H]+ 778.15. LCMS retention time (214 nm): 3.83
(R)-1-((S)-1-(2-(Adamantan-1-yl)ethyl)-4-((R)-1-(naphtha-
len-2-yl)-3-((S)-2-(((S)-2-(naphthalen-2-ylmethyl)piperazin-1-
yl)methyl)pyrrolidin-1-yl)propan-2-yl)piperazin-2-yl)ethanol
(18). Using the synthetic approach described in Figure 1 for the
synthesis of pyrrolidine-bis-piperazines compound 18 was
synthesized using the following reagents: Boc-L-2-naphthylala-
nine (R1), Boc-D-2-naphthylalanine (R2), Boc-D-threonine
(Bzl)-OH (R3), and 1-adamantaneacetic acid (R4). Final
crude product was puriﬁed by HPLC as described above.
LCMS (ESI+) Calcd for C51H69N5O: 768.55, found [M + H]+
768.25. LCMS retention time (214 nm): 3.70.
4 - ( ( ( R ) - 4 - ( ( S ) - 1 - C y c l o h e x y l - 3 - ( ( S ) - 2 - ( ( ( R ) - 2 -
(hydroxymethyl)piperazin-1-yl)methyl)pyrrolidin-1-yl)-
propan-2-yl)-1-(3,4-dichlorophenethyl)piperazin-2-yl)-
methyl)phenol (20). Using the synthetic approach described in
Figure 1 for the synthesis of pyrrolidine-bis-piperazines
compound 20 was synthesized using the following reagents:
Boc-L-Serine (Bzl) (R1), Boc-L-cyclohexylalanine (R2), Boc-D-
tyrosine (2-Br-Z)-OH (R3), and 3,4-dichlorophenylacetic acid
(R4). Final crude product was puriﬁed by HPLC as described
above. LCMS (ESI+) Calcd for C38H57Cl2N5O2: 686.40, found
[M + H]+ 686.15. LCMS retention time (214 nm): 3.38.
4-(((R)-1-(2-(Adamantan-1-yl)ethyl)-4-((S)-1-cyclohexyl-3-
((S)-2-(((R)-2-(hydroxymethyl)piperazin-1-yl)methyl)-
pyrrolidin-1-yl)propan-2-yl)piperazin-2-yl)methyl)phenol
(21). Using the synthetic approach described in Figure 1 for the
synthesis of pyrrolidine-bis-piperazines compound 21 was
synthesized using the following reagents: Boc-L-serine (Bzl)
(R1), Boc-L-cyclohexylalanine (R2), Boc-D-tyrosine (2-Br-Z)-
OH (R3), and 1-adamantaneacetic acid (R4). Final crude
product was puriﬁed by HPLC as described above. LCMS (ESI
+) Calcd for C42H69N5O2: 676.55, found [M + H]+ 676.30.
LCMS retention time (214 nm): 3.51.
( (R)-1-( ( (S)-1-((S)-2-( (R)-3-((R)-sec-Butyl) -4-(3 ,4-
dichlorophenethyl)piperazin-1-yl)-3-cyclohexylpropyl)-
pyrrolidin-2-yl)methyl)piperazin-2-yl)methanol (23). Using
the synthetic approach described in Figure 1 for the synthesis
of pyrrolidine-bis-piperazines compound 23 was synthesized
using the following reagents: Boc-L-serine (Bzl) (R1), Boc-L-
cyclohexylalanine (R2), Boc-D-isoleucine (R3), and 3,4-dichlor-
ophenylacetic acid (R4). Final crude product was puriﬁed by
HPLC as described above. LCMS (ESI+) Calcd for
C35H59Cl2N5O: 636.42, found [M + H]+ 636.20. LCMS
retention time (214 nm): 3.34.
((R)-1-(((S)-1-((S)-2-((R)-4-(2-(Adamantan-1-yl)ethyl)-3-
((R)-sec-butyl)piperazin-1-yl)-3-cyclohexylpropyl)pyrrolidin-
2-yl)methyl)piperazin-2-yl)methanol (24). Using the synthetic
approach described in Figure 1 for the synthesis of pyrrolidine-
bis-piperazines compound 24 was synthesized using the
following reagents: Boc-L-serine (Bzl) (R1), Boc-L-cyclo-
hexylalanine (R2), Boc-D-isoleucine (R3), and 1-adamantane-
acetic acid (R4). Final crude product was puriﬁed by HPLC as
described above. LCMS (ESI+) Calcd for C39H71N5O: 626.57,
found [M + H]+ 626.30. LCMS retention time (214 nm): 3.60.
( (R)-1-( ( (S)-1-( (R)-2-( (R)-3-((R)-sec-Butyl ) -4-(3,4-
dichlorophenethyl)piperazin-1-yl)-3-(naphthalen-2-yl)-
propyl)pyrrolidin-2-yl)methyl)piperazin-2-yl)methanol (32).
Using the synthetic approach described in Figure 1 for the
synthesis of pyrrolidine-bis-piperazines compound 32 was
synthesized using the following reagents: Boc-L-serine (Bzl)
(R1), Boc-D-2-naphthylalanine (R2), Boc-D-isoleucine (R3) and
3,4-dichlorophenylacetic acid (R4). Final crude product was
puriﬁed by HPLC as described above. LCMS (ESI+) Calcd for
C39H55Cl2N5O: 680.38, found [M + H]+ 680.10. LCMS
retention time (214 nm): 3.55.
(R)-1-((S)-1-(2-(Adamantan-1-yl)ethyl)-4-((R)-1-((S)-2-(((S)-
2-butylpiperazin-1-yl)methyl)pyrrolidin-1-yl)-3-(naphthalen-
2-yl)propan-2-yl)piperazin-2-yl)ethanol (54). Using the syn-
thetic approach described in Figure 1 for the synthesis of
pyrrolidine-bis-piperazines compound 1 was synthesized using
the following reagents: Boc-L-norleucine (R1), Boc-D-2-
naphthylalanine (R2), Boc-D-threonine (Bzl) (R3), and 1-
adamantaneacetic acid (R4). Final crude product was puriﬁed
by HPLC as described above. LCMS (ESI+) Calcd for
C44H69N5O: 684.55, found [M + H]+ 684.25. LCMS retention
time (214 nm): 3.70.
Animals. Experiments used male C57BL/6J mice (20−32 g
each, Jackson Laboratories, Bar Harbor, ME). Additional tests
used male mu-opioid receptor gene-disrupted “knockout” mice
(MOR KO) or kappa-opioid receptor gene-disrupted “knock-
out” mice (KOR KO), obtained from a breeding colony
established at the Torrey Pines Institute for Molecular Studies
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from homozygous breeding pairs of mice obtained from the
Jackson Laboratory. Mice were housed four per cage in a
temperature-controlled room. Cages were kept in a room with
12-h light/dark cycle with the lights on from 0700 to 1900 h
and food and water available ad libitum. All procedures with
mice were preapproved by the Torrey Pines Institute for
Molecular Studies Institutional Animal Care Committee,
operating under the OLAW approval number A4618-01, and
in accordance with the 2002 National Institutes of Health
Guide for the Care and Use of Laboratory Animals. Consistent
with these guidelines, ongoing statistical testing of data
collected was used to minimize the number of animals used,
within the constraints of necessary statistical power.
Chemicals. In all assays, TPI compounds were dissolved in
10% dimethyl sulfoxide, a concentration that did not produce
any detectable behavioral eﬀect. Morphine sulfate, naloxone,
nor-binaltorphimine (nor-BNI), and naltrindole were pur-
chased from Sigma-Aldrich (St. Louis, MO) and dissolved in
0.9% sterile saline.
Opioid Receptor Binding to Murine Brain Mem-
branes. The ability of TPI 2213 library samples to bind to
the three opioid receptors was determined by incubating
membrane protein with a receptor-selective radiolabeled
ligands and a 500 μM concentration of one of the TPI 2213
samples as described previously.7 Incubation times of 60 min
were used for the MOR-selective peptide [3H][D-Ala2,(Me)-
Phe4,Gly(ol)5]enkephalin ([3H]DAMGO) and 120 min for the
delta-opioid receptor (DOR) selective peptide [3H][D-
Pen2,Phe4,D-Pen5]enkephalin ([3H]DPDPE) using rat brain
homogenates and the kappa-opioid receptor (KOR) selective
ligand [3H]U69,593 at ﬁnal concentrations of 1−2 nM, in
guinea pig brain homogenates.4,5,36
Antinociceptive Testing. The 55 °C warm-water tail-
withdrawal assay was performed with mice as previously
described.16 Brieﬂy, water heated to 55 °C acted as a
nociceptive stimulus with the latency to withdraw the tail was
taken as the end point. Mice showing no response within 5 s
during the determination of baseline responses were excluded
from the experiment. After determining baseline control
responses, mice were administered vehicle or graded doses of
morphine or a TPI sample. All samples were each given as
single intraperitoneal (i.p.) injections with tail withdrawal
latencies measured 0.5, 1, 2, 3.5, 5, 8, and 24 h
postadministration unless otherwise stated. A cutoﬀ of 15 s
was used to avoid tissue damage; those mice failing to withdraw
their tails within this time were assigned a maximal
antinociceptive score of 100%. In the receptor selectivity
studies, the KOR-selective antagonist nor-BNI (10 mg/kg, i.p.)
was injected 24 h before TPI sample administration, whereas
the DOR-selective antagonist naltrindole (20 mg/kg, i.p.) was
administered 20 min prior to administration of the TPI sample.
For scaﬀold and positional screening studies, results are
presented as the sum of average responses at each time point
across all seven time points tested. For more detailed analysis
across time (selected TPI 2213-series individual samples),
antinociception at each time point was calculated as follows: %
antinociception = 100(test latency − control latency)/(15 −
control latency).
Respiratory Eﬀects. Respiration rates were recorded using
the automated, computer-controlled Comprehensive Lab
Animal Monitoring System (CLAMS) apparatus (Columbus
Instruments, Columbus, OH) as described previously.16 On the
day of the test, male C57BL/6J mice were habituated for 60
min in the apparatus cages, then administered (i.p.) vehicle or a
single dose of morphine or TPI sample. Following admin-
istration, mice were returned to chambers for 90 min with
respiration rate (breaths/min, or BPM) measured in 30-s
intervals.
Locomotor Activity. Spontaneous locomotor activity of
mice was simultaneously monitored in the CLAMS apparatus
for 90 min after i.p. administration of vehicle, morphine (10
mg/kg, i.p.), or TPI sample. As the animal moved through the
cage, infrared beams spaced every half inch along the
longitudinal axis were broken, allowing the calculation of
spontaneous locomotor activity (as ambulations) from adjacent
beam breaks as described earlier.17
Possible sedative eﬀects of the TPI-2213 individual samples
were assessed by rotorod performance, as modiﬁed from
previous protocols.37 Following seven habituation trials (the
last utilized as a baseline measure of rotorod performance),
mice were administered vehicle or a TPI-2213 series compound
(i.p.) and assessed after 10 min in accelerated speed trials (180
s max. latency at 0−20 rpm) over a 60 min period. Decreased
latencies to fall in the rotorod test indicate impaired motor
performance. Data are expressed as the percent change from
baseline performance.
Statistical Analysis. All dose−response lines were analyzed
by regression and ED50 (dose producing 50% antinociception)
values and 95% conﬁdence limits determined using each
individual data point by Prism5.0 software. Statistical
signiﬁcance of ED50 values was determined by evaluation of
the ED50 value shift via nonlinear regression modeling using
Prism 5.0. Student’s t tests comparing baseline and post-
treatment tail-withdrawal latencies were used to determine
statistical signiﬁcance for all tail-withdrawal data.38 Student’s t
tests were also used to determine statistical signiﬁcance of
summarized antinociceptive eﬀects of each individual sample
against the same eﬀect of morphine. Ranking of library samples
(see Figure 2) was performed with one-way ANOVA, with
signiﬁcant eﬀects further analyzed by Dunnet’s multiple
comparison post hoc testing using Prism 5.0 software. Data
for respiration and ambulation eﬀects were analyzed with one-
way ANOVA using Prism 5.0, with signiﬁcant eﬀects further
analyzed by Tukey’s HSD post hoc testing. Rotorod data were
analyzed via repeated measures ANOVA, with drug treatment
condition as a between-groups factor. For all repeated measures
ANOVAs simple main eﬀects and simple main eﬀect contrasts
are presented following signiﬁcant interactions. Where
appropriate, Tukey’s HSD post hoc tests were used to assess
group diﬀerences. All data are presented as mean ± SEM, with
signiﬁcance set at p ≤ 0.05.
Nonparametric Mathematical Analysis. For a given
sample X and control Y, the probability density of the random
variables X and Y was estimated using the median, quartiles,
and extrema (i.e., the ﬁve number summary) of their respective
data sets. Then, the probability, P, that the random variable Z =
X − Y is greater than zero (i.e., the probability that a randomly
chosen sample value exceeds a randomly chosen control value)
was calculated using Monte Carlo simulation on the estimated
distributions. Finally, these probability values were rank ordered
and compared to obtained signiﬁcances, which were compared
with the above statistical analyses to conﬁrm that there were no
substantial discrepancies.
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